TLX
Telix Pharmaceuticals Limited
NASDAQ: TLX · HEALTHCARE · BIOTECHNOLOGY
$10.43
-0.10% today
Updated 2026-04-29
Market cap
$3.53B
P/E ratio
—
P/S ratio
4.40x
EPS (TTM)
$-0.02
Dividend yield
—
52W range
$6 – $19
Volume
0.3M
Telix Pharmaceuticals Limited (TLX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-0.89%
Operating margin
1.94%
ROE
-1.86%
ROA
1.15%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 1999 | — | $-289000.00 | — | — | — |
| 2000 | — | $-497000.00 | — | — | — |
| 2011 | $23.48M | $-2.54M | -73.02% | -0.15% | -10.83% |
| 2013 | $20.95M | $-2.51M | 22.12% | -9.12% | -11.96% |
| 2014 | $28.34M | $5.43M | 20.17% | -17.89% | 19.18% |
| 2015 | $32.32M | $-132000.00 | 23.07% | -0.36% | -0.41% |
| 2016 | $29.40M | $-44000.00 | 27.39% | -0.10% | -0.15% |
| 2017 | $31.77M | $-6.38M | -0.01% | -20.04% | -20.07% |
| 2018 | $195142.00 | $-13.83M | 100.00% | -8,037.67% | -7,087.06% |
| 2019 | $3.48M | $-27.87M | -340.75% | -1,155.12% | -799.63% |
| 2020 | $5.21M | $-44.89M | -323.75% | -944.81% | -861.06% |
| 2021 | $7.60M | $-80.51M | -391.85% | -1,069.60% | -1,059.90% |
| 2022 | $160.10M | $-104.08M | 18.32% | -57.42% | -65.01% |
| 2023 | $502.55M | $5.21M | 62.56% | 10.32% | 1.04% |
| 2024 | $783.21M | $49.92M | 65.08% | 10.49% | 6.37% |
| 2025 | $1.21B | $-10.69M | 53.11% | 2.21% | -0.89% |